Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan

Table 2 Key cost and utility inputs

Cost (Yen)	Frequency	Value	Lower	Upper	Source
Drug cost
CTZ/TAZ	Daily	36,414			[29]
MEPM	Daily	2,589
AMK	Daily	714
Hospital resource
Mechanical ventilation	Daily (-Day 14)	9,500			[30]
Mechanical ventilation	Daily (Day 15-)	8,150			[30]
Adverse event cost
Septic shock	Per event	504,885		740,757	[10, 14, 29,30,31,32,33]
Multiorgan failure	Per event	504,885		740,757
Acute cardiac failure	Per event	182,758		189,860
Acute renal failure	Per event	94,800
Utility	Value		Lower	Upper	Source
Hospitalization with ventilator in ICU	-0.39		-0.402	0.3	[34]
Cured and discharged	0.8		0.66	1.0	[34]
Recovered in general ward	0.77		0.43	0.82	[35, 36]

CTZ/TAZ ceftolozane/tazobactam, MEPM Meropenem, AMK Amikacin, ICU Intensive Care Unit

ISSN: 1472-6963